334 related articles for article (PubMed ID: 26138461)
1. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.
Tripathi DM; Erice E; Lafoz E; García-Calderó H; Sarin SK; Bosch J; Gracia-Sancho J; García-Pagán JC
Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G301-9. PubMed ID: 26138461
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
[TBL] [Abstract][Full Text] [Related]
3. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
4. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats.
D'Amico M; Mejías M; García-Pras E; Abraldes JG; García-Pagán JC; Fernández M; Bosch J
Am J Physiol Gastrointest Liver Physiol; 2012 May; 302(10):G1191-8. PubMed ID: 22403792
[TBL] [Abstract][Full Text] [Related]
5. Comparative portal hypotensive effects as propranolol of vitamin D₃ treatment by decreasing intrahepatic resistance in cirrhotic rats.
Lee PC; Yang YY; Lee WP; Lee KC; Hsieh YC; Lee TY; Lin HC
J Gastroenterol Hepatol; 2015 Mar; 30(3):628-37. PubMed ID: 25187428
[TBL] [Abstract][Full Text] [Related]
6. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
Cerini F; Vilaseca M; Lafoz E; García-Irigoyen O; García-Calderó H; Tripathi DM; Avila M; Reverter JC; Bosch J; Gracia-Sancho J; García-Pagán JC
J Hepatol; 2016 Apr; 64(4):834-42. PubMed ID: 26686269
[TBL] [Abstract][Full Text] [Related]
7. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
[TBL] [Abstract][Full Text] [Related]
8. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
Coll M; Rodriguez S; Raurell I; Ezkurdia N; Brull A; Augustin S; Guardia J; Esteban R; Martell M; Genescà J
Hepatology; 2012 Nov; 56(5):1849-60. PubMed ID: 22610782
[TBL] [Abstract][Full Text] [Related]
9. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
[TBL] [Abstract][Full Text] [Related]
10. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.
Rodríguez-Vilarrupla A; Laviña B; García-Calderó H; Russo L; Rosado E; Roglans N; Bosch J; García-Pagán JC
J Hepatol; 2012 May; 56(5):1033-1039. PubMed ID: 22245887
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
12. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis.
Delgado MG; Gracia-Sancho J; Marrone G; Rodríguez-Vilarrupla A; Deulofeu R; Abraldes JG; Bosch J; García-Pagán JC
Am J Physiol Gastrointest Liver Physiol; 2013 Oct; 305(7):G496-502. PubMed ID: 23886859
[TBL] [Abstract][Full Text] [Related]
13. Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats.
Hsu SJ; Lee FY; Wang SS; Hsin IF; Lin TY; Huang HC; Chang CC; Chuang CL; Ho HL; Lin HC; Lee SD
Hepatology; 2015 May; 61(5):1672-84. PubMed ID: 25557829
[TBL] [Abstract][Full Text] [Related]
14. Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats.
Matei V; Rodríguez-Vilarrupla A; Deulofeu R; García-Calderó H; Fernández M; Bosch J; Garcia-Pagán JC
J Hepatol; 2008 Aug; 49(2):192-7. PubMed ID: 18534709
[TBL] [Abstract][Full Text] [Related]
15. The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats.
Rodríguez S; Raurell I; Ezkurdia N; Augustin S; Esteban R; Genescà J; Martell M
Liver Int; 2015 Feb; 35(2):326-34. PubMed ID: 24517276
[TBL] [Abstract][Full Text] [Related]
16. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats.
Loureiro-Silva MR; Cadelina GW; Iwakiri Y; Groszmann RJ
J Hepatol; 2003 Dec; 39(6):940-6. PubMed ID: 14642609
[TBL] [Abstract][Full Text] [Related]
17. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
18. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl
Zhang R; Chen J; Liu D; Wang Y
Front Med; 2019 Jun; 13(3):398-408. PubMed ID: 30820806
[TBL] [Abstract][Full Text] [Related]
19. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.
Lin HC; Huang YT; Yang YY; Lee PC; Hwang LH; Lee WP; Kuo YJ; Lee KC; Hsieh YC; Liu RS
J Gastroenterol Hepatol; 2014 May; 29(5):1073-82. PubMed ID: 24325631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
